boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us managing directors emmett cunningham nicholas galakatos robert w liptak scott requadt nicholas j simon michael steinmetz kurt c wheeler partners barry gertz michele park principalsadvisorsassociates dennis henner edward scolnick jeffrey leiden william young robert debenedetto kiran reddy ari brettman lazar dimitrov staff office south san francisco ca executive assistant christine esguerra  kurt c wheelermanaging director kurt wheeler has been managing director of clarus since the firm’s inception in  prior to clarus mr wheeler was a general partner at mpm capital a healthcare venture capital firm he has over  years of direct investment and industry experience within the healthcare sector mr wheeler was founder and ceo of incontrol nasdaqincl a medical device company sold to guidant prior to founding incontrol he was a principal with the mayfield fund focused on healthcare investing mr wheeler began his career with elli lilly  co mr wheeler holds a ba from brigham young university and a mba from northwestern university’s kellogg school current board seats avillion globus medical incnyse gmed flowonix previous board seats cardiac dimensions chf solutions acquired by gambro hemosense amexhem acquired by inverness medical incontrol nasdaqinclaquired by guidant intrathrerapeutics acquired by sulzer medica eyetech pharmaceuticals nasdaqeyet senorx nasdaqseno acquired by cr bard neuromed pharmaceuticals nasdaqzlcs sfj pharmaceuticals somaxon pharmaceuticals nasdaqsomx zogenix nasdaqzgnx clarus board seats fund clarus lifesciences ii lp sector biotechnology type defined exit team robert w liptak kurt c wheeler dennis henner emmett cunningham avillion avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products we offer a compelling opportunity to partner late phase therapeutic projects for approval in the eu and us and to accelerate their availability to the market avillion website  avillion signs clinical codevelopment agreement with merck to advance anti il af nanobody® in psoriasis  pfizer and avillion announce positive topline results for phase  bfore study of bosulif for firstline treatment  avillion announces dosing of first patients in phase  bfore trial to assess bosulif® bosutinib as firstline treatment for patients with chronic myelogenous leukemia  avillion elects ulf wiinberg ceo of lundbeck as chairman of its board of directors  avillion group partners with pfizer to codevelop bosulif® bosutinib as firstline treatment for patients with chronic myelogenous leukemia fund clarus lifesciences ii lp sector medical device type private team robert w liptak kurt c wheeler emmett cunningham flowonix medical flowonix medical is focused on developing better treatment options for the  million americans in chronic pain more than diabetes heart disease and cancer combined  our first product for delivery of intrathecal medication the prometra® programmable implantable pump is undergoing clinical trials  flowonix is headquartered in mount olive nj flowonix website  flowonix medical inc announces fda pmas approval of prometra ii  prometra pump from flowonix medical reaches important clinical milestone fund clarus lifesciences i lp sector medical device type public team robert w liptak kurt c wheeler globus medical inc nysegmed globus medical inc is focused on the development of products that enable spine surgeons to employ both fusion and nonfusion solutions to promote healing in patients with spinal disorders today globus is one of the fastest growing spinal implant companies in the world and a recognized leader in the development of motion sparing technology globus website  globus medical reports  first quarter results  globus medical announces acquisition of robotics developer excelsius surgical fund clarus lifesciences ii lp sector medical device type private team kurt c wheeler emmett cunningham neomend inc acquired by bard inc in october  neomend inc based in irvine ca has developed advanced surgical sealant adhesion barrier and applicator technologies based on its proprietary protein and polymer based hydrogel platform targeted surgical procedures include thoracic spine gynecology and general surgery the companys initial product progeltm pleural air leak sealant has received fda pma approval and is the only indicated surgical sealant in the us for sealing lung air leaks in thoracic surgery progel showed statistically significant reductions in intraoperative air leaks and length of hospital stay days in the pma trial fund clarus lifesciences i lp sector diagnostics  tools type public team scott requadt kurt c wheeler oxford immunotec ltd nasdaq oxfd oxford immunotec ltd develops and sells clinical diagnostic products based on its patented regulatory approved tspot® technology tspot is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection oxford immunotec’s first product tspot®tb is a revolutionary new blood test for diagnosing tuberculosis infection offering unmatched sensitivity oxford website  oxford immunotec ranked among deloitte’s  technology fast ™  oxford immunotec reports third quarter  financial results  oxford immunotec acquires immunetics inc  oxford immunotec selected to test new entrants for tb in uk national tender  oxford immunotec announces ce mark approval for tspot®cmv test  oxford immunotec announces availability of the tspot®cmv test in the united states  oxford immunotec reports first quarter  financial results  oxford immunotec reports first quarter  financial results  oxford immunotec reports fourth quarter and full year  financial results  dr peter wrightonsmith named uk bioindustry association bia entrepreneur of the year  oxford immunotec announces preliminary fourth quarter and fiscal  revenue and initiates  fiscal year guidance  oxford immunotec global plc announces closing of initial public offering and exercise of overallotment option  oxford immunotec global plc announces pricing of initial public offering  oxford immunotec wins place again on the sunday times hiscox tech track  fund clarus lifesciences i lp sector biotechnology type private team nicholas j simon kurt c wheeler emmett cunningham pearl therapeutics acquired by astrazeneca june  pearl therapeutics inc is a privatelyheld company focused on improving the treatment and prevention of widely prevalent respiratory disorders  pearl has licensed a suite of particle technologies from nektar therapeutics inc to rapidly advance their product candidates through development pearl website  pearl therapeutics to be acquired by astrazeneca for up to  billion fund clarus lifesciences ii lp sector medical device type private team kurt c wheeler emmett cunningham restoration robotics inc restoration robotics inc a privately held medical device company is dedicated to revolutionizing the field of hair transplantation by developing and commercializing a stateoftheart imageguided system artas™ system that enables follicular unit extraction restoration robotics website fund clarus lifesciences ii lp sector biotechnology type defined exit team robert w liptak scott requadt kurt c wheeler dennis henner michele park emmett cunningham sfj pharmaceuticals inc sfj pharmaceuticals sanfranciscojapan serves as a clinical development specialty pharma company with a focus on obtaining product approval in japan targeted candidates for development in japan are low risk compounds that are already approved or have a high likelihood of approval in the us with projected japan annual sales in excess of m to date sfj has entered definitive agreements with two major global pharma companies to fund phase  trials for oncology assets predetermined milestone payments to sfj shall be received on approval of the asset in prespecified countries sfj pharmaceuticals website  besponsa apppoved in the eu for adults patients with relapsed or refractory bcell precursor acute lymphoblastic leukemia  pfizers dacomitinib wins in phase  against astrazenecas iressa  pfizer phase  study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia  eisai receives approval in japan for anticancer agent levima®  eisai launches anticancer agent lenvimatm in the united states  us fda grants priority review status to nda for anticancer agent lenvatinib  us fda grants eisai’s investigational agent lenvatinib priority review designation for the treatment of advanced thyroid cancer  eisai submits first marketing authorization application for anticancer agent lenvatinib in japan  lenvatinib phase iii results show significant improvement in progressionfree survival in patients with radioiodinerefractory differentiated thyroid cancer  phase iii trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of radioiodinerefractory differentiated thyroid cancer fund clarus lifesciences i lp sector medical device type public team nicholas j simon kurt c wheeler michele park sientra inc nasdaq sien sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market in april  sientra secured  million in a series b financing coled by clarus ventures sientra website  sientra receives fda approval  sientra® announces pricing of initial public offering fund clarus lifesciences i lp sector biotechnology type public team kurt c wheeler emmett cunningham zogenix inc nasdaq zgnx zogenix inc is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat cns disorders and pain zogenix’ initial focus is the latestage development and commercialization of intraject® sumatriptan  a needlefree singleuse disposable subcutaneous delivery system that will compete in the  billion triptan segment of the migraine market  in august  zogenix secured  million in a financing coled by clarus ventures zogenix website  zogenix announces fda approval of  mg sumavelr dosepror sumatriptan injection needlefree delivery system  zogenix and battelle expand dosepro technology business agreement  zogenix reports third quarter  financial results  zogenix receives fda approval for zohydrotm er hydrocodone bitartrate extendedrelease capsules  zogenix begins promotion of migranalr nasal spray  zogenix and valeant pharmaceuticals enter exclusive copromotion agreement for migranalrnasal spray  zogenix launches improved migraine toolbox in conjunction with national migraine awareness month copyright   clarus ventures llc  all rights reserved clarus lifesciences ii lp private company information  bloomberg july    am et capital markets company overview of clarus lifesciences ii lp snapshot people company overview clarus lifesciences ii lp specializes in investments in startup early stage late stage and mature companies it seeks to invest in life science sector with a focus on biotechnology specialty pharmaceutical and medical technology companies that are developing innovative products for the treatment of human diseases the fund invests between  million and  million in its portfolio companies  main streetsuite cambridge ma united statesfounded in  phone  fax  key executives for clarus lifesciences ii lp dr nicholas g galakatos phd cofounder and managing director age  mr robert w liptak cpa managing director age  compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact clarus lifesciences ii lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version clarus lifesciences ii lp  current holdings  fintelio clarus lifesciences ii lp current holdings from f d investorclarus lifesciences ii lp current positions clarus lifesciences ii lp has disclosed  total holdings in their latest sec filings this investor has not filed a f which indicates it has under m in assets under management aum this investor has filed  activist d filings recently which suggests it takes an active role in influencing management clarus lifesciences ii lp s top industries are chemicals and allied products sic   overview sec filings dg predictive value all clarus lifesciences ii lp holdings are listed in the following table this data is sourced from dg and f filings green rows indicate new positions red rows indicate closed positions add this fundto your dashboard this is a list of d and g filings made since the last quarterly f report if any file dateformsecurity prevshares currentshares changepercent prev valuex current valuex changepercent ‑‑ sc da nstg  nanostring technologies inc     ‑‑ sc da catb  catabasis pharmaceuticals inc     ‑‑ sc da tlog  tetralogic pharmaceuticals corporation       fintel ir  find the right investors for your company instantly fintel ir combines the comprehensive fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy learn more now from the blog how to launch a hedge fund the piotroski score clarus lifesciences ii lp board of directors  bloomberg july    am et capital markets company overview of clarus lifesciences ii lp snapshotpeople  overviewboard memberscommittees clarus lifesciences ii lp insiders on board members name connectionsrelationshipstitleagethere is no company insiders data available other board members on board members name connectionsrelationshipstype of board membersprimary companyageklausbjörn rühne  relationshipsmember of advisory boardatp private equity partners request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most connected people on the clarus lifesciences ii lp boardnamerelationshipsklausbjörn rühne  relationships sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact clarus lifesciences ii lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us managing directors emmett cunningham nicholas galakatos robert w liptak scott requadt nicholas j simon michael steinmetz kurt c wheeler partners barry gertz michele park principalsadvisorsassociates dennis henner edward scolnick jeffrey leiden william young robert debenedetto kiran reddy ari brettman lazar dimitrov staff office south san francisco ca executive assistant teresa mccoy   michele park phdpartner michele park phd serves as a partner for the firm and leads the clarus cancer fund a novel investment model aimed at generating financial returns and amplifying scientific and medical impacts by donating a portion of the cancer fund’s returns to advance basic science research in cancer dr park joined clarus in  with six years of sellside equity research experience covering the biotechnology sector from  dr park was a research analyst at credit suisse first boston where she covered biotechnology stocks as a member of the firm’s us biotechnology team before joining csfb dr park was a biotechnology research analyst at us bancorp piper jaffray dr park received a phd in molecular biology from cornell university’s graduate school of biomedical sciences completing her phd dissertation at memorial sloankettering cancer center and a ba in molecular biology from princeton university michele is a member of curesearch’s catapult advisory council and represents clarus on the board of directors of lumos and as a board observer of sfj  previous board seats have included sientra nasdaqsien and board observer roles at achillion and  comentis clarus board seats fund clarus lifesciences ii lp sector biotechnology type public team nicholas j simon michele park achillion pharmaceuticals inc nasdaq achn achillion is a biopharmaceutical company focused on the discovery development and commercialization of novel small molecule inhibitors targeting infectious disease pipeline programs include a firstinclass hcv replicase inhibitor partnered with gilead and an hcv protease inhibitor additional drug candidates target treatment of hiv and bacterial infections achillion website fund clarus lifesciences i lp sector biotechnology type private team nicholas j simon dennis henner michele park comentis inc comentis inc is engaged in the discovery and development of smallmolecule drugs to treat neurovascular disease indications such as alzheimer’s disease amd and cognitive disorders  the company has two fundamental technology platforms  i betasecretase inhibitors for the treatment of alzheimer’s disease and ii nach receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders comentis website  comentis and anvyl announce formation of alpharmagen a joint venture to explore nicotinic modulators fund clarus lifesciences iii lp sector biotechnology type private team michele park lumos pharma lumos pharma based in austin texas is focused on developing novel therapies for patients with unmet medical needs in rare and neglected diseases lumos pharma is a proud awardee of the national institutes of health’s nih therapeutics for rare and neglected diseases trnd program the trnd program collaborates with biotechnology companies in the development of early stage technologies that show promise for the treatment of rare diseases the trnd program provides inkind scientific and financial support for the preclinical program to allow for the commencement of clinical trials in human subjects lumos website  lumos pharma raises  million in series b financing fund clarus lifesciences iii lp sector biotechnology type public team nicholas j simon michele park neothetics nasdaq neot neothetics is a clinicalstage company developing therapeutics for the aesthetics market their initial focus is on nonsurgical localized fat reduction and body contouring the company’s lead drug candidate is for the reduction of central abdominal bulging due to subcutaneous fat in nonobese patients the company has completed phase  development for lipo and plans to launch phase  trials in early  neothetics website  neothetics initiates pivotal phase  clinical trials for lipo the first noninvasive injectable drug candidate for reduction of subcutaneous abdominal fat fund clarus lifesciences ii lp sector biotechnology type defined exit team robert w liptak scott requadt kurt c wheeler dennis henner michele park emmett cunningham sfj pharmaceuticals inc sfj pharmaceuticals sanfranciscojapan serves as a clinical development specialty pharma company with a focus on obtaining product approval in japan targeted candidates for development in japan are low risk compounds that are already approved or have a high likelihood of approval in the us with projected japan annual sales in excess of m to date sfj has entered definitive agreements with two major global pharma companies to fund phase  trials for oncology assets predetermined milestone payments to sfj shall be received on approval of the asset in prespecified countries sfj pharmaceuticals website  besponsa apppoved in the eu for adults patients with relapsed or refractory bcell precursor acute lymphoblastic leukemia  pfizers dacomitinib wins in phase  against astrazenecas iressa  pfizer phase  study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia  eisai receives approval in japan for anticancer agent levima®  eisai launches anticancer agent lenvimatm in the united states  us fda grants priority review status to nda for anticancer agent lenvatinib  us fda grants eisai’s investigational agent lenvatinib priority review designation for the treatment of advanced thyroid cancer  eisai submits first marketing authorization application for anticancer agent lenvatinib in japan  lenvatinib phase iii results show significant improvement in progressionfree survival in patients with radioiodinerefractory differentiated thyroid cancer  phase iii trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of radioiodinerefractory differentiated thyroid cancer fund clarus lifesciences i lp sector medical device type public team nicholas j simon kurt c wheeler michele park sientra inc nasdaq sien sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market in april  sientra secured  million in a series b financing coled by clarus ventures sientra website  sientra receives fda approval  sientra® announces pricing of initial public offering copyright   clarus ventures llc  all rights reserved insider trading  clarus lifesciences ii lp  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  clarus lifesciences ii lp select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm tetralogic pharmaceuticals corp tlog clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner    direct view sale  pm tetralogic pharmaceuticals corp tlog clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner    direct view sale  pm tetralogic pharmaceuticals corp tlog clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner    direct view sale  pm tetralogic pharmaceuticals corp tlog clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner    direct view purchase  pm catabasis pharmaceuticals inc catb clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llc owner    direct view purchasea  pm aerie pharmaceuticals inc aeri clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner    direct view a indicate amendment filing stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na nanostring technologies inc nstg clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llc owner   indirect view option award  pm na nanostring technologies inc nstg clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llc owner   indirect view conversion  pm nana catabasis pharmaceuticals inc catb clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llc owner   direct view conversion  pm nana catabasis pharmaceuticals inc catb clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llc owner   direct view conversion  pm nana catabasis pharmaceuticals inc catb clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llc owner   direct view conversion  pm nana catabasis pharmaceuticals inc catb clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llc owner   direct view other  pm nana ophthotech corp opht clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner   direct view other  pm nana aerie pharmaceuticals inc aeri clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner   direct view conversion  pm na aerie pharmaceuticals inc aeri clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner   direct view conversion  pm na aerie pharmaceuticals inc aeri clarus lifesciences ii lpclarus ventures ii gp lpclarus ventures ii llcgalakatos nicholashenner dennisliptak robertsimon nicholassteinmetz michaelwheeler kurt owner   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  clarus lifesciences ii lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors clarus lifesciences ii lp check out list of companies and businesses related to clarus lifesciences ii lp find out clarus lifesciences ii lp address and contact details view other people related to clarus lifesciences ii lp  coworkers colleagues companions etc address co clarus ventures llc  main street suite  cambridge  ma companies related to clarus lifesciences ii lp cikcompany namepositioncompany addressachillion pharmaceuticals inc owner  george street new haven aerie pharmaceuticals inc owner  kit creek road suite  research triangle park tetralogic pharmaceuticals corp owner po box  paoli nanostring technologies inc owner  fairview avenue north seattle ophthotech corp owner one penn plaza th floor new york catabasis pharmaceuticals inc owner one kendall square bldg e suite b cambridge  clarus lifesciences ii lp on the web persons related to clarus lifesciences ii lp  achillion pharmaceuticals incnamepositioncityadvent healthcare  life sciences ii kg bostonadvent healthcare  life sciences ii lp bostonadvent international corpma bostoninternational limited partnership advent bostonpartners hls limited partnership advent ii bostonpartners limited partnership advent bostondavid apelianchief medical officer new havenatlas venture associates v lpwalthamatlas venture entrepreneurs fund v lpwalthamatlas venture fund v lp owner walthamatlas venture parallel fund va c vwalthamjoel c barrishchief scientific officer new havenjames c blair owner princetonclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgescheer davidnew havenwright davidnew havenliotta dennisnew havenmilind deshpandechief executive officer new havenassociates domainprincetondomain partners viii lpprincetondomain partners viii lp owner princetonbrian h dovey owner princetondp viii associates lpbostonolek elizabethnew havenmary kay fentonchief financial officer new havenjason s fishermandirector san diegojason s fishermandirector bostonjason s fishermandirector bostonjason s fishermandirector bostonjason s fishermandirector new havenjean francois formeladirector walthamgary e frashierdirector san diegogary e frashierdirector new havennicholas galakatoscambridgejames m garveydirector new havenfrashier garynew havenshah gautamnew havengilead sciences inc owner foster citykurt gravesdirector cambridgekurt gravesdirector new havenmichael g greydirector new havenbrian k halak owner princetondennis hennercambridgeab investor owner stockholmab investor owner stockholminvestor growth capital ltdguernsey channel islandsinvestor growth capital ltdguernseyfisherman jasonnew havenjohnson  johnsonnew brunswickjohnson  johnson development corp et alnew brunswicktruitt josephnew havenkim p kamdarprincetonmichael d kishbauchdirector cambridgemichael d kishbauchdirector new havenpeter kolchinskybostonpeter kolchinskybostonjeffrey leidencambridgedennis liottadirector new havenrobert liptakcambridgemartha e manningevp general counsel extonkay fenton marynew havenkishbauch michaelnew havengrey michaelnew havendeshpande milindnew havenjay moorin owner princetonsimon nicholasnew havenelizabeth a oleksvp and cmo new havenjohn c pottage jrsvp and chief medical officer new havenproquest associates iv llcprincetonproquest investments iv lpprincetonquaker bioventures ii lp owner philadelphiaqvt associates gp llc owner new yorkqvt associates gp llc owner new yorkqvt fund v lpnew yorkra capital healthcare fund lpbostonra capital healthcare fund lpbostonra capital management llc owner bostonra capital management llc owner bostonvan nostrand robertnew havenstefan ryserdirector new havendavid scheerdirector new havenkathleen k schoemaker owner princetonalain schreiberprincetonschroder venture managers ltd owner hamiltonschroder ventures international life sciences fund ii lphamiltonschroder ventures international life sciences fund ii lphamiltonschroder ventures international life sciences fund ii lphamiltonschroder ventures international life sciences fund ii strategic partners lphamiltonschroder ventures managers inchamiltongautam shahevp and chief compliance ofc new havennicholas simondirector cambridgenicholas simondirector new havensitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonsitco nominees ltd vc  as nominee of schroder ventures international life hamiltonmichael steinmetzcambridgesv nominees ltd as nominee of schroder ventures investments ltdhamiltonjesse i treu owner princetonjoseph truittchief commercial officer new havennostrand robert l vandirector melvillenostrand robert l vandirector new havennostrand robert l vandirector new havenfrank verwieldirector brisbanenicole vitullodirector richmondnicole vitullodirector princetonkurt wheelercambridgechristopher a whitedirector new havendavid p wrightdirector new havendavid p wrightdirector new havenpersons related to clarus lifesciences ii lp  aerie pharmaceuticals incnamepositioncityacmp iv llcsan franciscoacmp iv llcsan franciscoacp iv lp owner san franciscoacp iv lpsan franciscomehra anandbridgewatermehra anandbedminstervicente anido jrchief executive officer irvinevicente anido jrchief executive officer bedminsterdavid bondermanfort worthdavid bondermanfort worthlevy brianbedminstereric buatoismenlo parkeric buatoismenlo parkgerald d cagledirector bedminsterkopczynski caseybridgewaterkopczynski caseybedminsterclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgejanet l conwaybedminsterjames g coulterfort worthjames g coulterfort worthrichard croarkindirector irvineepstein davidresearch triangle parkepstein davidbridgewaterepstein davidbedminstergryska davidbedminstermack davidsan franciscomack davidbridgewatermack davidbedminsterhenner dennisbedminstertoit michael dudirector new yorkgeoffrey m duykdirector geoffrey m duykfort worthgeoffrey m duykfort worthgeoffrey m duykdirector fort worthforesite capital fund ii lpsan franciscoforesite capital fund iii lpsan franciscoforesite capital management ii llc owner san franciscoforesite capital management iii llcsan francisconicholas galakatoscambridgeduyk geoffreysan franciscoduyk geoffreybridgewaterduyk geoffreybedminstercagle geraldbedminstermurray a goldbergdirector murray a goldbergdirector bedminsterdavid w gryskadirector south san franciscodavid w gryskadirector bedminsterjames healymenlo parkjames healymenlo parkdennis hennercambridgemazzo jamesbedminsterconway janetresearch triangle parkconway janetbridgewaterconway janetbedminsterdaniel janneysan franciscodaniel janneysan franciscocasey c kopczynskichief scientific officer bedminsterbrian levychief medical officer rochesterbrian levychief medical officer bedminsterrobert liptakcambridgedavid henry macksan franciscojames v mazzodirector bedminsterbenjamin f mcgraw iiidirector irvinebenjamin f mcgraw iiibedminsterjulie mchughdirector chadds fordanand mehradirector menlo parkanand mehra owner menlo parkanand mehradirector menlo parkdelong mitchellbridgewaterthomas a mitropresident and coo irvinethomas a mitropresident and coo bedminstergoldberg murraybedminstergoldberg murraybedminsterguy p nohrasan franciscoguy p nohrasan franciscomichael powellmenlo parkmichael powellmenlo parkrubino richardbedminsterrichard j rubinochief financial officer franklin lakesrichard j rubinochief financial officer bedminsternicholas simoncambridgesofinnova management vii llcmenlo parksofinnova management vii llcmenlo parksofinnova venture partners vii l pmenlo parksofinnova venture partners vii l p owner menlo parkmichael steinmetzcambridgejames b tananbaumsan franciscomitro thomasbedminstervan haarlem thomasbridgewatervan haarlem thomasbedminstertpg group holdings sbs advisors inc fort worthtpg group holdings sbs advisors inc owner fort worthanido vicentebedminsterkurt wheelercambridgepersons related to clarus lifesciences ii lp  tetralogic pharmaceuticals corpnamepositioncityamgen inc owner thousand oaksamgen ventures llcthousand oakspecora andrewmalvernpecora andrewwyckoffcolin glenn begleychief scientific officer  svp malverngavin brendamalverngavin brendaphiladelphiaj kevin buchipresident  ceo j kevin buchipresident  ceo malvernjames h cavanaughcambridgeclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgeweng davidmalvernonsi douglasprincetonreed douglasdurhamnicholas galakatosbostonnicholas galakatoscambridgebrenda d gavindirector malverngeode capital management lp bostonmclendon georgemalvernsander gerbernew yorkjohn gillmalvernmary ann graydirector new yorkmary ann graydirector new yorkwerner haroldmalvernwerner haroldprincetonhealthcare partners vii lpcambridgehealthcare ventures vii lp owner cambridgekautsky helgamalverndennis hennersouth san franciscodennis hennercambridgehighbridge capital management llcnew yorkhudson bay capital management lp new yorkpatrick hutchisonmalvernlasersohn jackmalverngoldschmidt jamesmalvernwoody jamessan franciscowoody jimmalverngill johnmalverngill johnmalvernmichael d kishbauchflemingtonmichael d kishbauchdirector flemingtonaugustine lawlorcambridgelazard asset management llc new yorklinden advisors lp new yorklinden capital lpnew yorkrobert liptakbostonrobert liptakcambridgejohn w littlechildcambridgemckinlay markmalvernmckinlay markmalvernpete a meyerscfo  treasurer malvernpeter a meyerscfo  treasurer malvernsteinmetz michaelcambridgechristopher mirabellicambridgenomura holdings inctokyonomura securities international inc new yorkdouglas e onsidirector cambridgepandora select partners lpminneapolisschmitt paulmalvernschmitt paulwayneandrew l pecoradirector new yorkandrew l pecoradirector malverndouglas md reeddirector malvernlesley russellchief operating officer malvernpaul j schmittdirector waynepaul j schmittdirector bethlehempaul j schmittdirector bethlehemrichard l shermansee remarks malvernnicholas simoncambridgenicholas simoncambridgestate of new jersey common pension fund d trentonmichael steinmetzsan diegomichael steinmetzcambridgemichael steinmetzdirector cambridgetelemetry securities llc new yorkharold r wernercambridgekurt wheelerbostonkurt wheelercambridgewhitebox advisors llc minneapoliswhitebox combined partners lpminneapoliswhitebox convertible arbitrage partners lpminneapoliswhitebox general partner llcminneapoliswhitebox gt fund lpminneapolisjames n woodydirector malvernpersons related to clarus lifesciences ii lp  nanostring technologies incnamepositioncitymary tedd allenvp manufacturing seattlesaunders barneyseattlejoseph m beechemsvp research  development seattlej chad brownsvp sales  marketing seattleseeley bruceseattleseeley bruceseattlewayne burnssvp operations  admin seattlewaite charleskirklandclarus ventures ii gp lpcambridgeclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgeclarus ventures ii llccambridgej wayne cowenschief medical officer seattlebradford crutchfielddirector seattledraper associates l pmenlo parkdraper associates riskmasters fund ii llcmenlo parkdraper associates riskmasters fund llcmenlo parkdraper fisher jurvetson fund vii lpmenlo parkdraper fisher jurvetson fund vii lp owner menlo parkdraper fisher jurvetson partners vii llcmenlo parkelisha w finneydirector palo altokuruvilla finnycambridgekuruvilla finnycambridgejennifer scott fonstaddirector menlo parknicholas galakatosdirector bostonnicholas galakatosdirector cambridgeriordan garyseattledavid w ghesquieresvp corporate  business dev seattler bradley graypresident and ceo seattlenorden gregoryseattlefell hseattlerobert hershbergdirector seattlecowens jseattlejohnson jamesseattlejohnson jamesseattlefonstad jennifermenlo parkfonstad jenniferseattlecowens johnseattlejames a johnsonchief financial officer seattlejames a johnsonchief financial officer seattlebeechem josephseattlesuracesmith kathrynseattlefinny kuruvilladirector seattlefinny kuruvilladirector cambridgekirk malloydirector san diegoallen maryseattlemurdter naliniseattlegalakatos nicholascambridgegalaktos nicholascambridgegregory nordendirector madisongregory nordendirector seattletina susan novaseattleovp venture partners vi lp owner seattleovp venture partners vii lpseattleovp vi entrepreneurs fund lpseattleovp vii entrepreneurs fund lpseattlefell perryseattlegary s riordanseattlegray robertseattlebarney saunderssvp sales  marketing seattlebruce j seeleysvp  gm diagnostics seattlekathryn suracesmithseattlecharles p waite jrdirector sunnyvalecharles p waite jrdirector seattleburns wayneseattleyoung williamseattleyoung williamsseattlewilliam youngdirector rockvillewilliam youngseattlewilliam youngdirector seattlepersons related to clarus lifesciences ii lp  ophthotech corpnamepositioncitybolte alexnew yorkmichael g atiehevp cfo  cbo treasurer michael g atiehevpcfo  cbo treasurer new yorkbolte axelprincetonhenric bjorn bjarkesvp  cco new yorkaxel boltedirector south plainfieldaxel boltedirector new yorkpeacock bruceprincetondavid francis carrollsvp cfo and treasurer new yorkclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgeguyer davidnew yorkguyer davidprincetonthomas dyrbergdirector hellerupharrison evelynnew yorkharrison evelynprincetonnicholas galakatosdirector bostonnicholas galakatosdirector cambridgenicholas galakatosdirector cambridgedavid r guyerchief executive officer new yorkdavid r guyerchief executive officer new yorkdavid r guyerchief executive officer new yorkhbm healthcare investments cayman ltd owner grand caymandennis hennersouth san franciscodennis hennercambridgesimon henrynew yorkrobert liptakbostonrobert liptakcambridgegiebel lutzprincetonross michaelprincetongalakatos nicholasprincetongalakatos nicholasnew yorkas novo owner bagsvaerdas novo owner hellerupsamir chandrakant patelpresident new yorksamir chandrakant patelpresident new yorksamir chandrakant patelpresident new yorkbruce peacockcfo  cbo new yorkbruce peacockcfo  cbo new yorkdavid e redlickdirector new yorkmichael jay rossdirector michael jay rossdirector bostonpatel samirnew yorkpatel samirprincetonglenn sblendoriopresident cfo and treasurer new yorkglenn sblendoriodirector new yorkglenn sblendoriodirector new yorknicholas simoncambridgenicholas simoncambridgeian f smithdirector cambridgetodd n smithsvp  cco new yorkmichael steinmetzsan diegomichael steinmetzcambridgesv life sciences fund iv gp lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv strategic partners l pbostonsvlsf iv llc owner bostonbiancardi thomasnew yorkdyrberg thomasnew yorkdyrberg thomasnew yorkdyrberg thomasprincetonkeith westbysvp  coo new yorkkurt wheelerbostonkurt wheelercambridgebarbara a woodsvpgeneral counselsecretary melvillebarbara a woodsvpgeneral counselsecretary new yorkpersons related to clarus lifesciences ii lp  catabasis pharmaceuticals incnamepositioncityburt a adelmandirector cambridgeadvanced technology ventures viii lpbostonatv associates viii llcbostonkenneth batedirector cambridgethomajan chriscambridgethomajan christophercambridgeclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgedeirdre a cunnanesvp general counsel cambridgejoanne m donovancmo svp clinical development cambridgenicholas galakatosdirector bostonjean georgedirector lexingtonedward k hibbencambridgesanderson iancambridgegeorge jeancambridgeleiden jeffreycambridgemilne jillcambridgemilne jillcambridgemilne jillcambridgemichael jirousekchief scientific officer cambridgebate kennethcambridgemichael d kishbauchdirector cambridgeron lauferdirector gaithersburgleflore maggiecambridgemedimmune ventures inc owner gaithersburgjirousek michaelcambridgejirousek michaelcambridgejirousek michaelcambridgeross michaelcambridgeross michaelcambridgejill c milneceo and president cambridgerick modichief business officer cambridgegalakatos nicholascambridgeandrew john nicholschief scientific officer cambridgelaufer roncambridgemichael jay rossdirector ian c sandersonchief financial officer cambridgesv life sciences fund v gp lpbostonsv life sciences fund v lpbostonsv life sciences fund v strategic partners lpbostonsvlsf v llc owner boston potentially same personnamecitycountryclarus lifesciences ii lpcambridgema clarus closes second fund  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital clarus closes second fund february   by pehub administrator print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub clarus closes second fund continue reading on pe hub writes clarus ventures has closed its second fund with  million in limited partner commitments the bostonbased vc firm focuses on life sciences opportunities and spun out of mpm capital in    press release clarus ventures llc “clarus ventures” a leading life sciences venture capital firm announced today the single close of clarus lifesciences ii lp “clarus ii” a  million fund in limited partner commitments this is the second investment fund formed and managed by clarus ventures since the firm was established in    clarus ii will invest  million in biotechnology specialtypharmaceutical and medical technology companies that are developing innovative products for the treatment of human diseases the firms first fund has committed  percent of its proceeds to date “we have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies” said robert liptak a clarus ventures managing director “these include companies with strong growth in revenue and profitability such as globus medical products near commercialization such as sientra pelikan oxford and zogenix and those with breakthrough products and technologies such as aerovance centauruscomentis esbatech pearl proacta sarcode taligen and variation we plan to follow a similar investment strategy for clarus ii with the diversity and depth of our team we believe we can leverage our experience to identify and help grow leading companies in the life sciences field”  the limited partner base for clarus ii was effectively the same as in clarus i a small select group of new highquality investors who knew the firm well also participated  the clarus ventures team is led by nicholas galakatos dennis henner jeffrey leiden robert liptak nicholas simon michael steinmetz and kurt wheeler an established group of investment professionals with deep and complementary backgrounds within the life sciences industry the team uniquely balances broad investing expertise with leadership experience inmajor biotechnology and pharmaceutical companies about clarus venturesfounded by a group of accomplished investment professionals withextensive and complementary industry backgrounds clarus ventures is a life sciences venture capital firm with a team that has a long history of success in creating value internal operating experience combined with longstanding relationships with key opinion leaders and industry thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity clarus ventures augments its core expertise of investing in biopharmaceuticals and medical technology with deep and diverse expertise in research and development commercialization business development and operations management at the global level the firm has  billion under management and has offices in cambridge mass and south san francisco ca for additional information on clarus ventures please visithttpwwwclarusventurescom   print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub clarus closes second fund continue reading on pe hub writes sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian bain capital double impact funds two companies by iris dorbian kkr to buy nature’s bounty from carlyle by luisa beltran blackrock leads funding round for fintech platform icapital by iris dorbian platinum equity to buy united site services by luisa beltran the pe hub podcast episode two by staff report private equity jobs of the week priceline kpmg novaquest are hiring by eamon murphy the carveout curveball by pehublogger network clarus lifesciences ii lp  sec form  insider trading screener  openinsider openinsider latest latest cluster buys latest insider trading all filings latest insider purchases latest insider purchases k latest officer purchases k latest ceocfo purchases k latest insider sales latest insider sales k latest officer sales k latest ceocfo sales k top top officer purchases today top officer purchases past week top officer purchases past month top insider purchases today top insider purchases past week top insider purchases past month top insider sales today top insider sales past week top insider sales past month by symbol officer purchases k today officer purchases k past week officer purchases k past month officer sales k today officer sales k past week officer sales k past month officer sales k today no optex officer sales k past week no optex officer sales k past month no optex insider purchases of penny stocks past month insider sales of penny stocks past month charts contact clarus lifesciences ii lp  sec form  insider trading screenercik   address co clarus ventures llc  main street suite  cambridge ma  general tickers insider sh price  lqdty m date filing date all dates custom latest day last  days last  week last  weeks last  month last  months last  months last  months last  year last  years last  years    trade date all dates custom latest day last  days last  week last  weeks last  month last  months last  months last  months last  year last  years last  years    filing delay n days ago transaction filing p  purchase s  sale a  grant d  sale to iss g  gift f  tax m  option ex x  option ex c  cnv deriv w  inherited no deriv multiple days traded k own chg  industry all sectors except funds agriculture forestry fish mining construction manufacturing transportation  utilities wholesale trade retail trade financial services closedend funds insider title   officer     cob     ceo     pres     coo     cfo     gc     vp   director    own   other group by filing company company totals num filings num insiders num officers traded k own chg  sort by filing date trade date ticker symbol trade value max results page clear realtime csv options alerts  results        tccntdwmms x filing date trade date ticker insider nameinsider title trade type  share price shares traded shares owned own chg value traded d ret w ret m ret m ret m  tlogclarus lifesciences ii lps  sale m  tlogclarus lifesciences ii lps  sale m  tlogclarus lifesciences ii lps  sale m  tlogclarus lifesciences ii lps  sale realtime csv options alerts contact us aamended filing dderivative transaction in filing usually option exercise eerror detected in filing mmultiple transactions in filing earliest reported transaction date and weighted average transaction price s  salesale of securities on an exchange or to another persons  saleoesale of securities on an exchange or to another person after option exercisef  taxpayment of exercise price or tax liability using portion of securities received from the companyp  purchasepurchase of securities on an exchange or from another person return to top copyright   openinsidercom all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft clarus lifesciences  learn   web results aol search skip over navigation search the web web images images how edwards is different  tavrbyedwardscom ad · tavrbyedwardscom learn about edwards makers of heart valves used in tavr watch the patient video doctor discussion guide clarus at amazoncom  buy clarus at amazon ad · amazoncom buy clarus at amazon free shipping on qualified orders dewalt  off  deals save up to  for dad stanley  off  deals clarus antifungal solution  save  off today ad · blackfridaydealsco​clarusantifung redeem your special deal on clarus antifungal solution hurry expires soon forensic science college ad · wwwaiuonlineedu​forensics take classes in forensic science at aiu  online start today searches related toclarus lifesciences clarus group clarus healthcare clarus linen systems web results boston and san francisco based health   clarus ventures httpswwwclarusfundscom clarus is a life sciences capital firm with a team that has a long history of success in creating value claris lifesciences limited  sterile injectables  wwwclarislifesciencescom welcome claris lifesciences limited a bse listed company is a multibusiness enterprise and the holding company of claris injectables  a whollyowned subsidiary  clarus lifesciences ii lp private company information  httpswwwbloombergcomresearchstocksprivatesnapshotasp clarus lifesciences ii lp company research  investing information find executives and the latest company news clarus lifesciences  lp  nanostring tech insider  httpswwwtiprankscominsidersclaruslifescienceslp clarus lifesciences  lp ten percent owner at nanostring tech nstg has a  success rate when buying and selling stocks clarus lifesciences i lp  zogenix insider transactions  httpswwwtiprankscominsidersclaruslifesciencesilp clarus lifesciences i lp ten percent owner at zogenix zgnx has a  success rate when buying and selling stocks clarus lifesciences i lp top holdings httpswhalewisdomcomfilerclaruslifesciencesilp detailed profile of clarus lifesciences i lp portfolio of holdings sec filings include f quarterly reports dg events and more clarus ventures closes  million fund to invest in life  httpswwwbostonglobecombusinessclarusventures with capital continuing to pour into the biopharmaceutical industry clarus ventures said tuesday it has closed a  million life sciences fund oversubscribed by  secgems clarus lifesciences i lp  vbiv  wwwsecgemscomcikallsecfilings learn up to the minute information about clarus lifesciences i lp  vbiv   including connections with peoplecompanies sec filings including ownership and  clarus lifesciences ventures trademark information wwwtrademarkiacomclaruslifesciencesventureshtml clarus lifesciences ventures is a trademark and brand of clarus ventures llc filed to uspto on thursday june   the clarus lifesciences ventures covers  clarus lifesciences iii lp acquires securities of essa  wwwnewswirecanewsreleasesclaruslifesciencesiiilpacquires cambridge ma jan   clarus lifesciences iii lp acquires securities of essa pharma inc how edwards is different  tavrbyedwardscom ad · tavrbyedwardscom learn about edwards makers of heart valves used in tavr watch the patient video doctor discussion guide clarus at amazoncom  buy clarus at amazon ad · amazoncom buy clarus at amazon free shipping on qualified orders dewalt  off  deals save up to  for dad stanley  off  deals clarus antifungal solution  save  off today ad · blackfridaydealsco​clarusantifung redeem your special deal on clarus antifungal solution hurry expires soon forensic science college ad · wwwaiuonlineedu​forensics take classes in forensic science at aiu  online start today searches related toclarus lifesciences clarus group clarus healthcare clarus linen systems next search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network